



SEQUENCE LISTING

<110> Watson, John W.
Andrews, Paul L.R.
Woods, Anthony J.

<120> PROKINETIC AGENTS FOR TREATING GASTRIC HYPMOTILITY AND RELATED DISORDERS

<130> 16613 (PC9731A)

<140> 09/476,253
<141> 1999-12-30

<160> 12

<170> PatentIn version 3.2

<210> 1
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (1)..(1)
<223> Phe is stereoisomer

<220>
<221> misc_feature
<222> (4)..(4)
<223> Trp is stereoisomer

<220>
<221> misc_feature
<222> (5)..(5)
<223> Xaa is Orn

<220>
<221> misc_feature
<222> (7)..(7)
<223> Xaa is Pen

<220>
<221> misc_feature
<222> (8)..(8)
<223> Thr is Thr-NH subscript 2

<400> 1

Phe Cys Tyr Trp Xaa Thr Xaa Thr
1 5

<210> 2

<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (2)..(2)
<223> Ala is stereoisomer

<220>
<221> misc_feature
<222> (7)..(7)
<223> Gly is Gly-NH subscript 2

<400> 2

Tyr Ala Phe Asp Val Val Gly
1 5

<210> 3
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (2)..(2)
<223> Ala is stereoisomer

<220>
<221> misc_feature
<222> (7)..(7)
<223> Gly is Gly-NH subscript 2

<400> 3

Tyr Ala Phe Glu Val Val Gly
1 5

<210> 4
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>

```
<221> misc_feature  
<222> (4)..(4)  
<223> Pro is Pro-NH subscript 2
```

```
<400> 4
```

Tyr Pro Phe Pro
1

```
<210> 5  
<211> 4  
<212> PRT  
<213> Artificial Sequence
```

```
<220>  
<223> Synthetic peptide
```

```
<220>  
<221> misc_feature  
<222> (3)..(3)  
<223> Phe is substituted with a methyl group
```

```
<220>  
<221> misc_feature  
<222> (4)..(4)  
<223> Pro is Pro-NH subscript 2 and is stereoisomer
```

```
<400> 5
```

Tyr Pro Phe Pro
1

```
<210> 6  
<211> 9  
<212> PRT  
<213> Artificial Sequence
```

```
<220>  
<223> Synthetic peptide
```

```
<400> 6
```

Arg Pro Pro Gly Phe Ser Pro Phe Arg
1 5

```
<210> 7  
<211> 10  
<212> PRT  
<213> Artificial Sequence
```

```
<220>  
<223> Synthetic peptide
```

```
<400> 7
```

Lys Arg Pro Pro Gly Phe Ser Pro Phe Arg
1 5 10

<210> 8
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (9)..(9)
<223> Arg is des-Arg

<400> 8

Arg Pro Pro Gly Phe Ser Pro Phe Arg
1 5

<210> 9
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (10)..(10)
<223> Arg is des-Arg

<400> 9

Lys Arg Pro Pro Gly Phe Ser Pro Phe Arg
1 5 10

<210> 10
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (9)..(9)
<223> Arg is des- Arg

<400> 10

Arg Pro Pro Gly Phe Ser Pro Leu Arg
1 5

<210> 11
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (7)..(7)
<223> Phe is stereoisomer

<400> 11

Arg Pro Pro Gly Phe Ser Phe Phe Arg
1 5

<210> 12
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> misc_feature
<222> (1)..(1)
<223> Arg is stereoisomer

<220>
<221> misc_feature
<222> (4)..(4)
<223> Xaa is trans-4-hydroxy-Pro

<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa is Beta(2-thienyl)-Ala

<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa is [D]-1,2,3,4-tetrahydroquinolin-3-yl-carbonyl

<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa is (3as,7as)-octahydroindol-2-yl-carbonyl

<400> 12

Arg Arg Pro Xaa Gly Xaa Ser Xaa Xaa Arg
1 5 10